dos Santos, R. S., Guzmán Llorens, D., Perez-Serna, A. A., Nadal, A., & Marroqui Esclapez, L. (2023). Deucravacitinib, a tyrosine kinase 2 pseudokinase inhibitor, protects human EndoC-βH1 β-cells against proinflammatory insults.
Chicago Style Citationdos Santos, Reinaldo S., Daniel Guzmán Llorens, Atenea Alexandra Perez-Serna, Angel Nadal, and Laura Marroqui Esclapez. Deucravacitinib, a Tyrosine Kinase 2 Pseudokinase Inhibitor, Protects Human EndoC-βH1 β-cells against Proinflammatory Insults. 2023.
MLA Citationdos Santos, Reinaldo S., et al. Deucravacitinib, a Tyrosine Kinase 2 Pseudokinase Inhibitor, Protects Human EndoC-βH1 β-cells against Proinflammatory Insults. 2023.
Warning: These citations may not always be 100% accurate.